Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2412616 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?
Curr Atheroscler Rep
July 2025
Department of Medicine - DIMED, Clinica Medica 1, University of Padova, Padua, 35128, Italy.
Purpose Of Review: Apolipoprotein C-III (ApoC-III) plays a pivotal role in triglyceride (TG) metabolism by inhibiting lipoprotein lipase and hepatic clearance of TG-rich lipoproteins, contributing to hypertriglyceridaemia and elevated cardiovascular risk, as well as a high risk of acute pancreatitis. This review aims to summarize current evidence on ApoC-III inhibition strategies.
Recent Findings: Current treatments targeting Apo C-III include two antisense oligonucleotides (ASOs) (volanesorsen and olezarsen), and a small interfering RNA (siRNA) (plozasiran).
Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors.
Am J Cardiovasc Drugs
July 2025
Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, TX, USA.
Hypertriglyceridemia has been proposed as a risk factor for atherosclerotic cardiovascular disease (ASCVD). Triglycerides (TG) are viewed as a marker for remnant cholesterol in triglyceride-rich lipoproteins, as this remnant cholesterol has been identified as a causal risk factor for ASCVD. The limited number of effective treatments for elevated TG has fueled the search for novel pharmacotherapy options, and multiple medication classes are being explored.
View Article and Find Full Text PDFSmall Interfering RNA (siRNA) in Dyslipidemia: A Systematic Review on Safety and Efficacy of siRNA.
J Exp Pharmacol
May 2025
Department of General Medicine, University of Rwanda, Kigali, Rwanda.
Introduction: RNA interference (RNAi) therapy represents an evolving advancement in the management of dyslipidemia. One prominent form of RNAi therapy is small interfering RNA (siRNA), which has emerged as a promising therapeutic strategy. This study aims to critically analyze the efficacy and safety of siRNA in the treatment of dyslipidemia.
View Article and Find Full Text PDFNovel Therapeutics for Familial Chylomicronemia Syndrome.
Curr Atheroscler Rep
April 2025
Cardiology Division, Department of Medicine, Universidade Federal de São Paulo (UNIFESP), Rua José de Magalhães, São Paulo, SP, 34004026 - 090, Brazil.
Purpose Of Review: This review discusses new treatment approaches for familial chylomicronemia syndrome (FCS), a rare disorder affecting triglyceride metabolism. The focus is on antisense oligonucleotides (ASO) and small-interfering RNA (siRNA) therapies targeting APOC3 and angiopoietin-like protein 3 (ANGPTL3).
Recent Findings: Volanesorsen, an ASO targeting APOC3, has shown effectiveness in managing FCS, multifactorial chylomicronemia, and familial partial lipodystrophy, but its use is limited by thrombocytopenia.
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. Reply.
N Engl J Med
April 2025
Stanford University, Palo Alto, CA.